Mark Enyedy

Track

Insider profile

Currently holds positions in LogicBio Therapeutics Inc, Akebia Therapeutics Inc and ImmunoGen Inc

Performance

Overall performance
2.5
Performance over holding periods
2.5
30 days 90 days 120 days
Average return 8% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
4 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director LogicBio Therapeutics Inc March 17, 2020 -
Independent Director Akebia Therapeutics Inc Dec. 12, 2018 -
President, Chief Executive Officer, Director ImmunoGen Inc May 16, 2016 -
Independent Director Keryx Biopharmaceuticals Inc Sept. 11, 2017 - Dec. 12, 2018
Independent Director Fate Therapeutics Inc July 1, 2012 - May 2, 2018
Director Proteostasis Therapeutics Inc June 30, 2014 - Jan. 1, 2015
Chief Executive Officer, Director Proteostasis Therapeutics Inc None -
Mark Enyedy's trades of ImmunoGen Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
US ImmunoGen Inc (IMGN)
Transaction date
Planned sale
Price
393.71
Quantity 76,957 -10.9%
Value US$2,855,977
US ImmunoGen Inc (IMGN)
Transaction date
Proposed sale
Price
375.11
Quantity 38,606
Value US$1,126,510
US ImmunoGen Inc (IMGN)
Transaction date
Proposed sale
Price
79.96
Quantity 22,471
Value US$4,871,775
US ImmunoGen Inc (IMGN)
Transaction date
Sale
Price
16.96
Quantity 992,397 -64.2%
Value US$16,831,053
US ImmunoGen Inc (IMGN)
Transaction date
Sale
Price
16.61
Quantity 1,020,000 -69.8%
Value US$16,942,200
US ImmunoGen Inc (IMGN)
Transaction date
Proposed sale
Price
16.61
Quantity 1,020,000
Value US$16,938,477
US ImmunoGen Inc (IMGN)
Transaction date
Sale
Price
18.15
Quantity 8,636 -1.9%
Value US$156,743
US ImmunoGen Inc (IMGN)
Transaction date
Sale
Price
17.45
Quantity 986,521 -68.7%
Value US$17,214,791
US ImmunoGen Inc (IMGN)
Transaction date
Proposed sale
Price
17.45
Quantity 995,157
Value US$17,367,363
US ImmunoGen Inc (IMGN)
Transaction date
Planned sale
Price
4.99
Quantity 55,222 -11.3%
Value US$275,558
US ImmunoGen Inc (IMGN)
Transaction date
Planned sale
Price
5.60
Quantity 51,070 -9.5%
Value US$285,992
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-02-06 2024-02-05
US ImmunoGen Inc (IMGN)
PlS Planned sale
76,957 -10.9%
393.71
US$2,855,977 		76,957 -10.9% 393.71 US$2,855,977
2024-02-05 2024-02-05
US ImmunoGen Inc (IMGN)
PrS Proposed sale
38,606
375.11
US$1,126,510 		38,606 375.11 US$1,126,510
2023-08-04 2023-08-04
US ImmunoGen Inc (IMGN)
PrS Proposed sale
22,471
79.96
US$4,871,775 		22,471 79.96 US$4,871,775
2023-08-04 2023-08-04
US ImmunoGen Inc (IMGN)
S Sale
992,397 -64.2%
16.96
US$16,831,053 		992,397 -64.2% 16.96 US$16,831,053
2023-08-04 2023-08-03
US ImmunoGen Inc (IMGN)
S Sale
1,020,000 -69.8%
16.61
US$16,942,200 		1,020,000 -69.8% 16.61 US$16,942,200
2023-08-03 2023-08-03
US ImmunoGen Inc (IMGN)
PrS Proposed sale
1,020,000
16.61
US$16,938,477 		1,020,000 16.61 US$16,938,477
2023-08-04 2023-08-02
US ImmunoGen Inc (IMGN)
S Sale
8,636 -1.9%
18.15
US$156,743 		8,636 -1.9% 18.15 US$156,743
2023-08-04 2023-08-02
US ImmunoGen Inc (IMGN)
S Sale
986,521 -68.7%
17.45
US$17,214,791 		986,521 -68.7% 17.45 US$17,214,791
2023-08-02 2023-08-02
US ImmunoGen Inc (IMGN)
PrS Proposed sale
995,157
17.45
US$17,367,363 		995,157 17.45 US$17,367,363
2020-02-25 2020-02-24
US ImmunoGen Inc (IMGN)
PlS Planned sale
55,222 -11.3%
4.99
US$275,558 		55,222 -11.3% 4.99 US$275,558
2019-02-25 2018-02-22
US ImmunoGen Inc (IMGN)
PlS Planned sale
51,070 -9.5%
5.60
US$285,992 		51,070 -9.5% 5.60 US$285,992